Beyond Air (XAIR)
(Delayed Data from NSDQ)
$0.39 USD
-0.02 (-5.74%)
Updated Sep 17, 2024 04:00 PM ET
After-Market: $0.40 +0.01 (1.52%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.39 USD
-0.02 (-5.74%)
Updated Sep 17, 2024 04:00 PM ET
After-Market: $0.40 +0.01 (1.52%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Zacks News
Beyond Air, Inc. (XAIR) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Beyond Air (XAIR) delivered earnings and revenue surprises of 6.90% and 5.14%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
New Strong Buy Stocks for July 25th
by Zacks Equity Research
BSVN, OKTA, SVM, SFIX and XAIR have been added to the Zacks Rank #1 (Strong Buy) List on July 25, 2024.
Alterity (ATHE) Up on Interim Data From Advance MSA Study
by Zacks Equity Research
Alterity (ATHE) posts positive interim data from the phase II ATH434-202 study evaluating its lead candidate ATH434 for treating patients with multiple system atrophy. Stock rises.
All You Need to Know About Beyond Air (XAIR) Rating Upgrade to Strong Buy
by Zacks Equity Research
Beyond Air (XAIR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Beyond Air (XAIR) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Beyond Air (XAIR), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Beyond Air, Inc. (XAIR) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Beyond Air (XAIR) delivered earnings and revenue surprises of 23.40% and 33.33%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Factors to Note Ahead of Guidewire's (GWRE) Q3 Earnings Release
by Zacks Equity Research
Guidewire's (GWRE) fiscal third-quarter performance is likely to have been driven by strengthening subscription revenues.
Beyond Air (XAIR) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Beyond Air (XAIR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Beyond Air, Inc. (XAIR) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Beyond Air, Inc. (XAIR) delivered earnings and revenue surprises of 18.03% and 20.20%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Beyond Air, Inc. (XAIR) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Beyond Air, Inc. (XAIR) delivered earnings and revenue surprises of 2.17% and 70.65%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Beyond Air, Inc. (XAIR) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Beyond Air, Inc. (XAIR) delivered earnings and revenue surprises of -52.27% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Beyond Air, Inc. (XAIR) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Beyond Air, Inc. (XAIR) delivered earnings and revenue surprises of -2.38% and 100%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for January 27th
by Zacks Equity Research
ARAY, XAIR, and EMKR have been added to the Zacks Rank #5 (Strong Sell) List on January 27, 2022
Implied Volatility Surging for Beyond Air (XAIR) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Beyond Air (XAIR) stock based on the movements in the options market lately.
Beyond Air, Inc. (XAIR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Beyond Air, Inc. (XAIR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Beyond Air, Inc. (XAIR) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Beyond Air, Inc. (XAIR) delivered earnings and revenue surprises of -63.16% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Beyond Air, Inc. (XAIR) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Beyond Air, Inc. (XAIR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Beyond Air (XAIR) is in Overbought Territory: What's Next?
by Zacks Equity Research
Beyond Air (XAIR) has moved higher as of late, but there could definitely be trouble on the horizon for this company
Will Beyond Air, Inc. (XAIR) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Beyond Air, Inc. (XAIR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Share Gain in Core Markets to Aid Medtronic (MDT) Q4 Earnings
by Zacks Equity Research
Growing momentum in capital equipment purchases might have aided Medtronic (MDT) Q4 earnings.
4 Biotech Stocks Set to Outpace Q1 Earnings Estimates
by Zacks Equity Research
Let us take a look at some drug/biotech stocks that are poised to beat on first-quarter earnings.
Beyond Air, Inc. (XAIR) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Beyond Air, Inc. (XAIR) delivered earnings and revenue surprises of -6.45% and -25.50%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Beyond Air, Inc. (XAIR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Beyond Air, Inc. (XAIR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will AIT Therapeutics, Inc. (XAIR) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
AIT Therapeutics, Inc. (XAIR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate AIT Therapeutics, Inc. (XAIR) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
AIT Therapeutics, Inc. (XAIR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.